NCT04092894View on ClinicalTrials.gov

Suvorexant and Sleep/Delirium in ICU Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 28, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

July 1, 2025

Conditions
InsomniaSleep FragmentationSleep Initiation and Maintenance DisordersPostoperative Delirium
Interventions
DRUG

Suvorexant 20 mg

Administration of oral Suvorexant 20 mg

DRUG

Placebo oral tablet

Administration of oral placebo (same non-identifiable form as active comparator)

Trial Locations (2)

10467

RECRUITING

Montefiore Medical Center/Albert Einstein college of Medicine, The Bronx

02115

RECRUITING

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Beth Israel Deaconess Medical Center

OTHER